|
Daniel Pavin is a partner in the Corporate Practice and is resident in Covington's London office.
Mr. Pavin has broad non-contentious and contentious experience, with an emphasis on advising companies for whom intellectual property rights are of paramount importance. In particular, Mr. Pavin advises life sciences clients on their licensing, partnering, collaboration and other strategic and commercial agreements, and on the IP aspects of mergers, acquisitions and strategic investments in the life sciences and technology sectors. His contentious experience includes advising on contract disputes. Chambers UK (2012) characterises him as "an accomplished lawyer who is commercially minded and easy to work with."
Mr. Pavin also has particular expertise in data protection and data security. He has advised clients on a wide range of matters in these areas, including document and data retention policies, data security breaches and contested subject access requests.
Representative Matters
- Pharming Group NV on its strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture and commercialisation of new products based on the Pharming technology platform, in which SIPI will have commercialisation rights for the Chinese market for all new products developed and Pharming will retain global rights ex-China.
- UCB in relation to its strategic partnership with Synosia Therapeutics in which Synosia granted UCB a licence for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications, both compounds being in Phase II clinical development for the treatment of Parkinson’s disease.
- Minster Pharmaceuticals PLC, an AIM-quoted drug development company specializing in compounds for the treatment of neurological and psychiatric conditions, on intellectual property aspects of its recommended takeover by Proximagen Neuroscience PLC.
- Biocompatibles International plc on numerous transactional matters including:
- An option agreement with a major multinational Japanese pharmaceutical company in respect of Biocompatibles’ Drug-Eluting Bead Products in Japan;
- Distribution agreements with (among others) SciClone Pharmaceuticals and RITA Medical Systems, Inc (now AngioDynamics, Inc) in respect of Biocompatibles’ DC and LC Bead Products; and
- The sale of Biocompatibles’ cardiovascular business to Abbott Laboratories and eyecare business to the Cooper Group.
- Australian anti-infective drug development company, Biota Holdings Limited, on:
- UK intellectual property aspects of its acquisition of the key assets and programs of UK-based antibacterial drug discovery company, Prolysis Limited; and
- Its collaboration and licence agreement with a major multinational pharmaceutical company headquartered in Europe relating to a series of antivirals aimed at the treatment of respiratory syncytial virus (RSV).
- A global medical technology company in respect of a dispute regarding endeavors obligations in a patent and know-how licence for stabilization technology.
Honors and Rankings
- Chambers UK, Life Sciences: Transactional (2012-2013)
- Super Lawyers - London, Computer and IT Law (2013)
- Chambers UK, Best of the UK - Data Protection (2009-2011)
- PLC Which Lawyer?, Highly Recommended: Life Sciences - Commercial and Partnering, England (2008-2012)
- IAM Patent 1000 - The World’s Leading Patent Practitioners (2012-2013)
- The International Who's Who of Life Sciences Lawyers (2011-2012)
- Legal 500 UK, IT and Telecoms (2011-2012)
- Legal 500 UK, Pharmaceuticals and Biotechnology (2011)
- IAM Licensing 250 – The World’s Leading Patent and Technology Licensing Lawyers (2010-2011)
Publications and Speeches
- "Optimising the Agreement Structure," Pharmaceutical Licensing Group UK Training Course (3/7/2012)
- "Key Considerations for European M&A in the Life Sciences Sector," PLC Life Sciences Handbook 2012 (2012), Co-Author
- "Negotiation of Life Sciences Collaboration and Licence Agreements," Negotiating, Understanding and Drafting Commercial Contracts for the Pharmaceutical Industry Seminar (11/14/2011)
|
|